Adults with obesity or overweight and a history of heart disease now have a drug shown to cut their risk of heart attack, stroke, and cardiovascular death. The SELECT trial, a large randomized study of once-weekly semaglutide at 2.4 mg, found that the drug lowered major adverse cardiovascular events, or MACE, to 6.5% compared with 8.0% on placebo. The U.S. Food and Drug Administration used those results to approve Wegovy for this specific cardiovascular indication, making it the first weight-loss drug cleared to reduce serious heart problems in people who are overweight or obese. The approval extended a pattern already visible in earlier trials of GLP-1 receptor agonists in patients with type 2 diabetes, raising a broader question: could millions of people already taking these drugs for weight management alone be quietly gaining heart protection they were never prescribed?
Why semaglutide’s cardiovascular signal matters beyond diabetes
For years, the cardiovascular benefits of GLP-1 drugs were documented almost exclusively in people with type 2 diabetes. The SUSTAIN-6 trial tested semaglutide in patients with type 2 diabetes at high cardiovascular risk and demonstrated a reduction in major cardiovascular events. A separate trial, LEADER, showed that liraglutide, a different GLP-1 receptor agonist, also reduced MACE in a similar high-risk diabetes population. Those findings were significant but limited in scope. They applied to patients who already had diabetes, leaving open the question of whether the heart benefits came from glucose control, weight loss, or some other mechanism tied to GLP-1 receptor activation.
The SELECT trial changed that calculus. It enrolled adults with established cardiovascular disease and a body mass index of 27 or higher but explicitly excluded anyone with diabetes. By isolating the drug’s effect in a non-diabetic population, the trial separated the cardiovascular signal from blood sugar management. The result, a 20% relative reduction in the combined endpoint of cardiovascular death, nonfatal heart attack, or nonfatal stroke, suggested that semaglutide’s heart benefits operate through pathways that go beyond glycemic control.
That distinction carries real weight for the tens of millions of Americans who meet obesity criteria but do not have diabetes. According to the National Institute of Diabetes and Digestive and Kidney Diseases, more than 40% of U.S. adults are classified as obese. Many of those individuals carry elevated cardiovascular risk without a diabetes diagnosis. If semaglutide reduces heart events in this group, the eligible population for cardiovascular protection through GLP-1 drugs expands dramatically.
SELECT trial data and the FDA’s Wegovy approval
The SELECT trial, registered as ClinicalTrials.gov NCT03574597, tested once-weekly subcutaneous semaglutide at 2.4 mg against placebo. Participants had pre-existing cardiovascular disease and were overweight or obese but did not have diabetes. The primary endpoint was MACE, defined as cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke. The investigators reported their findings in the New England Journal of Medicine, confirming that semaglutide 2.4 mg lowered these events compared with placebo.
The FDA acted on those findings by approving Wegovy, the branded version of semaglutide 2.4 mg, to reduce the risk of cardiovascular death, heart attack, and stroke in adults with established cardiovascular disease and obesity or overweight. In its announcement, the agency noted that the MACE rate was 6.5% in the semaglutide group versus 8.0% on placebo. That 1.5 percentage point absolute difference translates into roughly one fewer major cardiovascular event for every 67 patients treated, a meaningful number when applied across a large population.
The approval was notable because it created a new treatment category. Previous cardiovascular risk-reduction drugs, such as statins and blood pressure medications, were not specifically indicated for adults with obesity as the qualifying condition. The FDA’s decision positioned Wegovy as the first treatment approved to reduce serious heart problems specifically in adults with obesity or overweight, a framing the agency itself used in its announcement. It also implicitly recognized obesity as a modifiable cardiovascular risk factor worthy of direct pharmacologic targeting, not just lifestyle counseling.
Unanswered questions about real-world heart protection
The SELECT trial provides strong evidence within its study population, but several gaps remain. The trial enrolled patients with established cardiovascular disease, meaning they had already experienced a heart attack, stroke, or related event. Whether semaglutide prevents first-time cardiovascular events in people with obesity but no prior heart disease is an open question that the existing data cannot answer. Primary prevention, as opposed to secondary prevention in patients with known disease, would require a different trial design and likely a much larger study.
Subgroup data also remain limited. The topline MACE results do not break down event rates by age, sex, or race in enough detail to know whether certain groups benefit more or less than others. Given longstanding disparities in cardiovascular outcomes, particularly for Black and Hispanic patients, clinicians and policymakers will want to know whether GLP-1 therapies narrow or widen those gaps. Until more granular analyses are published, assumptions about uniform benefit across all demographic groups are speculative.
Duration of therapy is another unresolved issue. SELECT followed participants for several years, but it did not answer how long patients must stay on semaglutide to maintain cardiovascular protection, or what happens if they stop. Weight tends to return when GLP-1 drugs are discontinued, and it is unclear whether any vascular or anti-inflammatory benefits persist after treatment ends. These questions are especially relevant given the cost of therapy and the reality that many patients may not be able to remain on the drug indefinitely.
Real-world adherence could further dilute or amplify the benefits seen in a tightly controlled trial. In practice, patients may miss doses, cycle on and off the drug due to side effects, or face insurance barriers that interrupt treatment. Gastrointestinal symptoms are common with semaglutide and can lead some people to discontinue therapy. If those who stop are also at highest cardiovascular risk, the protective effect observed in SELECT may not fully translate outside the trial setting.
Implications for patients already taking GLP-1 drugs
For people currently using semaglutide or other GLP-1 agonists solely for weight management, the SELECT findings are both encouraging and incomplete. The trial suggests that in individuals with obesity and established cardiovascular disease, semaglutide at the 2.4 mg dose meaningfully lowers the risk of heart attack, stroke, and cardiovascular death. However, SELECT did not include participants who were taking lower doses, nor did it enroll people using GLP-1 drugs purely for cosmetic or modest weight loss without significant cardiovascular risk factors.
That distinction matters because many prescriptions in clinical practice are written for people who are overweight or mildly obese but do not yet have diagnosed heart disease. For these patients, it is premature to assume the same degree of cardiovascular protection demonstrated in SELECT. They may still benefit from weight loss itself, which can improve blood pressure, lipid levels, and sleep apnea, but whether semaglutide adds a direct cardioprotective effect beyond those changes is unknown.
The dose used in SELECT also raises practical questions. Wegovy for weight management is typically titrated up to 2.4 mg weekly, matching the trial regimen, but some patients remain on lower maintenance doses to improve tolerability. It is not clear whether submaximal dosing confers the same cardiovascular benefit. Clinicians and patients will need to balance the goal of reaching the studied dose against the risk of side effects that might undermine adherence.
How clinicians and patients might navigate the new evidence
In the near term, the most straightforward application of the SELECT data is in secondary prevention: adults with obesity or overweight who already have cardiovascular disease and can tolerate semaglutide at the approved dose. For this group, Wegovy now joins statins, antiplatelet agents, and blood pressure medications as part of a comprehensive risk-reduction strategy. Insurance coverage may also be more justifiable when the indication is preventing heart attacks and strokes, not just managing weight.
For patients without established cardiovascular disease, the calculus is more nuanced. Clinicians may reasonably discuss the potential for heart protection as a possible but unproven benefit, while emphasizing that the primary evidence base supports semaglutide for weight loss and, in people with diabetes, for glycemic control and cardiovascular risk reduction. Shared decision-making should include a frank discussion of cost, side effects, and the likelihood that long-term therapy will be needed to sustain benefits.
Ultimately, SELECT has shifted the conversation about GLP-1 drugs from cosmetic weight loss toward cardiometabolic disease modification. Whether that shift will extend to the broader population of people using these medications remains to be seen. As additional data emerge, the central question will persist: are today’s weight-loss prescriptions quietly doubling as heart-protection strategies, or will future trials reveal that cardiovascular benefit is tightly linked to specific doses, risk profiles, and clinical contexts? For now, the evidence is strongest for those already living with heart disease-and only time and further research will determine how far that protection can reach.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
